Enoxaparin sodium

also known as enoxaparin · Lovenox · Clexane · enoxaparine · RP54563 · XRP4563 · Klexane · clexan · +13 more

Other / unclassified targets SERPINC1 via activation

Developed for: venous thromboembolism · COVID-19 · pulmonary embolism · thrombotic disease · blood coagulation disease · myocardial infarction · acute coronary syndrome · coronary artery disorder
+65 more
· fetal growth restriction · pneumonia · preeclampsia · cancer · cirrhosis of liver · intermediate coronary syndrome · malignant pancreatic neoplasm · pregnancy disorder · ST-elevation myocardial infarction · acute myocardial infarction · infertility disorder · ischemic stroke · non-small cell lung carcinoma · obesity disorder · osteoarthritis, hip · placental insufficiency · pregnancy loss, recurrent, 4 · small cell lung carcinoma · thrombophilia · viral pneumonia · acute respiratory distress syndrome · atrial fibrillation · basilar artery occlusion · brain injury · cardiac valvular defect · cardiovascular disorder · chronic liver failure · COVID-19–associated multisystem inflammatory syndrome in adults · end stage renal failure · esophageal cancer · female infertility · gastric cancer · gastroesophageal cancer · habitual spontaneous abortion · heart failure · hemorrhagic stroke · intracranial embolism · kidney disorder · myocardial ischemia · nephrotic syndrome · pancreatic adenocarcinoma · placental abruption · portal vein thrombosis · pregnancy disorder with abortive outcome · protein S deficiency · psoriasis · radiation-induced disorder · spinal cord injury · strictly posterior acute myocardial infarction · vein disorder · vulvodynia · acute respiratory failure · antiphospholipid syndrome · arterial occlusion · carotid artery dissection · chronic obstructive pulmonary disease · digestive system neoplasm · disease of bone structure · heart disorder · intracerebral hemorrhage · isolated splenic vein thrombosis · osteoarthritis, knee · staphylococcus aureus infection · thrombophlebitis · vertebral artery dissection
Investigated by: Sanofi · University of Utah · Assistance Publique - Hôpitaux de Paris · Boehringer Ingelheim · Massachusetts General Hospital · Azidus Brasil
+284 more
· Johns Hopkins All Children's Hospital · University Hospital, Geneva · University of Iowa · Weill Medical College of Cornell University · Aventis Pharmaceuticals · Beijing Anzhen Hospital · Beth Israel Deaconess Medical Center · Brigham and Women's Hospital · Bristol-Myers Squibb · CONKO-Studiengruppe · Canadian Institutes of Health Research (CIHR) · Chemi S.p.A. · Children's Hospital of Philadelphia · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Hamilton Health Sciences Corporation · Helsinki University Central Hospital · Les Laboratoires des Médicaments Stériles · Maria Fareri Children's Hospital · McMaster University · Medical University of Vienna · New York Presbyterian Hospital · North Shore Medical Center · Peking Union Medical College Hospital · Sheffield Teaching Hospitals NHS Foundation Trust · The Cleveland Clinic · Thrombosis Research Institute · Unity Health Toronto · University Hospital of Saint-Etienne · University Hospital, Brest · University of Manitoba · University of Sao Paulo · University of Sao Paulo General Hospital · University of Texas Southwestern Medical Center · University of Vermont Medical Center · Yale University · ASST Fatebenefratelli Sacco · AVANTI · Academy of Finland · Ahmed Elgazzar Hospital · Ain Shams University · Al Ain Hospital · Alberta Health services · Alexandre Tran · Amgen · Aotearoa Clinical Trials · AstraZeneca · Auckland City Hospital · Aurora Clinical Research · Australasian Society for Infectious Diseases · Australian and New Zealand Intensive Care Research Centre · BJC HealthCare · Barnes-Jewish Hospital · Bayer · Beijing Chuiyangliu Hospital · Beijing Friendship Hospital · Beijing Hospital · Beijing Obstetrics and Gynecology Hospital · Beneficência Portuguesa de São Paulo · Blau Farmaceutica S.A. · Brazilian Clinical Research Institute · Brazilian Research In Intensive Care Network · CH du Puy en Velay, Hôpital Emile Roux · CHU Hôpital Maison Blanche, 45 Rue Cognacq-Jay 51092 REIMS Cedex · CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang · Cairo University · Calydial · Canadian Critical Care Trials Group · Canadian Heart Research Centre · Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network · Cardiff University · Centre Hospitalier Universitaire Vaudois · Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal · Centre de dialyse d'Alès · Centre hospitalier de Chambéry · all 290 on the full record

Regulatory milestones approvals, filings & regulatory actions · 10 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Thorinane	—	2016-09-14	europa.eu ↗
Label expansions (8)	US (FDA)	LOVENOX (PRESERVATIVE FREE)	—	1995-03-09 – 2000-11-17	fda.gov ↗
Approved	US (FDA)	LOVENOX (PRESERVATIVE FREE)	—	1993-03-29	fda.gov ↗

Trials 172 · started per year

today

US approved 1993

EU approved 2016

1993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT02704052	Mar 2016 → Jul 2018	pulmonary embolism, venous thromboembolism	University of Utah	Completed	No outcome recorded
Phase 111 trials
Phase 1	NCT07312851	Jan → Jun 2026	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT06517563	Aug → Dec 2024	blood coagulation disease	VarmX B.V.	Completed	No outcome recorded
Phase 1	NCT04976465	Jan 2018 → Jul 2025 overdue	pregnancy disorder, systemic lupus erythematosus	Qilu Hospital of Shandong University	Recruiting	No outcome recorded
Phase 1	NCT03363477	Sep → Dec 2015	—	Rovi Pharmaceuticals Laboratories	Completed	No outcome recorded
Phase 1	NCT02232802	Aug → Dec 2014	—	Chemi S.p.A.	Completed	No outcome recorded
Phase 1	NCT02081950	Mar 2014	—	Chemi S.p.A.	Completed	No outcome recorded
Phase 1	NCT02152423	Jun 2013 → Jan 2014	acute coronary syndrome	University of Monastir	Completed	No outcome recorded
Phase 1	NCT01692158	Mar → Nov 2013	—	Azidus Brasil	Completed	No outcome recorded
Phase 1	NCT01692171	Feb → Oct 2013	—	Azidus Brasil	Completed	No outcome recorded
Phase 1	NCT01014403	Nov 2009 → May 2011	traumatic brain injury, venous thromboembolism	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 1	NCT02171559	Aug → Sep 2008	—	Boehringer Ingelheim	Completed	No outcome recorded

Phase 1/22 trials · 1 met primary
Phase 1/2	NCT04402762	Dec 2019 → Apr 2020	—	Indonesia University	Completed	Met primary
Phase 1/2	NCT01945879	Jan 2003 → Apr 2004	malignant pancreatic neoplasm	CONKO-Studiengruppe	Completed	No outcome recorded
Phase 228 trials · 1 met primary · 3 missed
Phase 2	NCT07499037	Jan 2027 → Sep 2029 expected	heart failure, pneumonia	University Hospital Ostrava	Not yet recruiting	No outcome recorded
Phase 2	NCT06531525	Aug 2024 → Dec 2026 expected	pregnancy disorder, protein S deficiency	Peking University People's Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT05895136	Jul 2024 → Oct 2026 expected	chronic liver failure, cirrhosis of liver	European Foundation for Study of Chronic Liver Failure	Recruiting	No outcome recorded
Phase 2	NCT06004674	Dec 2023 → Mar 2026 overdue	—	Endeavor Health	Recruiting	No outcome recorded
Phase 2	NCT06118957	Oct 2023 → Jul 2024	venous thromboembolism	University of Utah	Completed	No outcome recorded
Phase 2	NCT04354155	Jun 2020 → Jun 2021	COVID-19, venous thromboembolism	Johns Hopkins All Children's Hospital	Completed	No outcome recorded
Phase 2	NCT04377997	May 2020 → Jun 2022	COVID-19, cardiovascular disorder	Massachusetts General Hospital	Unknown	No outcome recorded
Phase 2	NCT03812328	Feb → Oct 2019	venous thromboembolism	Tetherex Pharmaceuticals Corporation	Completed	No outcome recorded
Phase 2	NCT03339349	Nov 2017 → Jun 2019	pulmonary embolism, venous thromboembolism	University of Utah	Completed	No outcome recorded
Phase 2	NCT03251963	Sep 2017 → Mar 2019	venous thromboembolism	University of Utah	Completed	Missed primary
Phase 2	NCT03200613	Sep 2017 → Jul 2019	spinal cord injury, venous thromboembolism	McMaster University	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT03212365	Jul 2017 → Jun 2019	pulmonary embolism, venous thromboembolism	University of Utah	Completed	No outcome recorded
Phase 2	NCT03003390	Apr 2017 → Aug 2019	venous thromboembolism	Yale University	Terminated	Missed primary
Phase 2	NCT03254511	Jul 2016 → Dec 2017	esophageal cancer	Mashhad University of Medical Sciences	Unknown	No outcome recorded
Phase 2	NCT02411292	Mar 2015 → Mar 2016	pulmonary embolism, venous thromboembolism	University of Utah	Completed	No outcome recorded
Phase 2	NCT02159287	Jan 2014 → Feb 2016	intracranial embolism	Shiraz University of Medical Sciences	Unknown	No outcome recorded
Phase 2	NCT01817257	Dec 2013 → Feb 2015	cancer, pulmonary embolism, thrombotic disease, venous thromboembolism	Cardiff University	Terminated	No outcome recorded
Phase 2	NCT01149304	Jun 2009 → Nov 2017	metastasis from malignant tumor of colon, radiation-induced disorder	University of Magdeburg	Completed	Met primary
Phase 2	NCT00908960	May 2009 → Apr 2012	cancer	Beth Israel Deaconess Medical Center	Completed	Missed primary
Phase 2	NCT00874484	Mar 2009 → Apr 2011	vulvodynia	Western Galilee Hospital-Nahariya	Completed	No outcome recorded
Phase 2	NCT00916669	Jul 2008 → Jul 2010	small cell lung carcinoma	Massachusetts General Hospital	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT00633061	Jun 2008 → Jun 2011	childhood malignant neoplasm, prosthesis-related infectious disease, vascular occlusion disorder, venous thromboembolism	University of Texas Southwestern Medical Center	Terminated	No outcome recorded
Phase 2	NCT00426127	Nov 2006 → Jan 2009	malignant pancreatic neoplasm	University of Iowa	Terminated	No outcome recorded
Phase 2	NCT01051778	Jun 2006 → Nov 2009	habitual spontaneous abortion	Cairo University	Completed	No outcome recorded
Phase 2	NCT00375609	May 2006 → Jan 2007	venous thromboembolism	Portola Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00331838	May 2006 → Jun 2007	venous thromboembolism	Sanofi	Completed	No outcome recorded
Phase 2	NCT00306254	Mar 2006 → Jul 2007	venous thromboembolism	Pfizer	Completed	No outcome recorded
Phase 2	NCT00402467	Feb → Nov 2004	venous thromboembolism	Bayer	Completed	No outcome recorded

Phase 2/38 trials · 1 met primary
Phase 2/3	NCT06662253	Jan 2025 → Jun 2026 overdue	venous thromboembolism	Alexandre Tran	Not yet recruiting	No outcome recorded
Phase 2/3	NCT04924322	May 2022 → Apr 2027 expected	vein disorder	Yale University	Recruiting	No outcome recorded
Phase 2/3	NCT04990830	Feb → Apr 2021	acute respiratory distress syndrome	Istanbul University	Completed	No outcome recorded
Phase 2/3	NCT04372589	May 2020 → May 2021	COVID-19, pneumonia	University of Manitoba	Completed	Mixed
Phase 2/3	NCT04558892	Oct 2015 → Nov 2018	nephrotic syndrome	Military Institute od Medicine National Research Institute	Terminated	Met primary
Phase 2/3	NCT01590173	Jan 2012 → Jul 2016	infertility disorder	National and Kapodistrian University of Athens	Completed	No outcome recorded
Phase 2/3	NCT00785421	Apr 2004 → Jan 2009	pancreatic adenocarcinoma	CONKO-Studiengruppe	Completed	No outcome recorded
Phase 2/3	NCT00077844	Jan 2004 → Sep 2005	—	Sanofi	Completed	Mixed
Phase 353 trials · 4 met primary · 12 missed
Phase 3	NCT06628778	Apr 2027 → Apr 2034 expected	venous thromboembolism	Johns Hopkins All Children's Hospital	Not yet recruiting	No outcome recorded
Phase 3	NCT07796737	Dec 2026 → Dec 2029 expected	pregnancy loss, recurrent, 4	General University Hospital, Prague	Not yet recruiting	No outcome recorded
Phase 3	NCT07140211	Oct 2025 → Aug 2030 expected	puerperal disorder, venous thromboembolism	Marc Blondon	Recruiting	No outcome recorded
Phase 3	NCT06494878	Apr 2025 → Aug 2030 expected	venous thromboembolism	University of Calgary	Not yet recruiting	No outcome recorded
Phase 3	NCT06153394	Jun 2024 → Feb 2025 overdue	liver disorder, thrombophilia, thrombotic disease	Western University, Canada	Not yet recruiting	No outcome recorded
Phase 3	NCT05848713	Oct 2023 → Mar 2028 expected	pneumonia	University of Manitoba	Recruiting	No outcome recorded
Phase 3	NCT04762992	Jul 2022 → Jul 2026 overdue	fetal growth restriction, preeclampsia	Centro Hospitalar de Lisboa Central	Enrolling by invitation	No outcome recorded
Phase 3	NCT05878899	May 2022 → Mar 2023	venous thromboembolism	University Hospital, Geneva	Completed	No outcome recorded
Phase 3	NCT04528888	Nov 2020 → Jun 2021	COVID-19, blood coagulation disease, viral pneumonia	Massimo Girardis	Unknown	No outcome recorded
Phase 3	NCT04600141	Nov 2020 → Oct 2021	COVID-19	University of Sao Paulo	Completed	No outcome recorded
Phase 3	NCT04492254	Oct 2020 → Nov 2021	COVID-19	Thrombosis Research Institute	Terminated	Missed primary
Phase 3	NCT04486508	Jul 2020 → Apr 2021	COVID-19	Rajaie Cardiovascular Medical and Research Center	Completed	Missed primary
Phase 3	NCT04483960	Jul 2020 → Jul 2025	COVID-19	University of Melbourne	Unknown	No outcome recorded
Phase 3	NCT04646655	Jul 2020 → Oct 2022	COVID-19, thrombotic disease	ASST Fatebenefratelli Sacco	Completed	Missed primary
Phase 3	NCT04485429	Jul 2020 → Dec 2022	COVID-19	D'Or Institute for Research and Education	Withdrawn	No outcome recorded
Phase 3	NCT04444700	Jul 2020 → May 2021	COVID-19, blood coagulation disease, severe acute respiratory syndrome, venous thromboembolism	University of Sao Paulo General Hospital	Completed	Missed primary
Phase 3	NCT04400799	Jun 2020 → Feb 2022	COVID-19, venous thromboembolism	University of Zurich	Terminated	Missed primary
Phase 3	NCT04408235	Jun 2020 → Jun 2021	COVID-19, blood coagulation disease, viral pneumonia	University Hospital of Modena	Unknown	Missed primary
Phase 3	NCT04362085	May 2020 → May 2021	COVID-19	Unity Health Toronto	Completed	Missed primary
Phase 3	NCT04345848	Apr 2020 → Jun 2021	COVID-19	University Hospital, Geneva	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT04401293	Apr 2020 → May 2021	COVID-19	Northwell Health	Completed	No outcome recorded
Phase 3	NCT03083184	Feb 2018 → Dec 2026 expected	—	University Hospital, Clermont-Ferrand	Recruiting	No outcome recorded
Phase 3	NCT02984384	Apr 2017 → Feb 2022	thrombotic disease	Major Extremity Trauma Research Consortium	Completed	Met primary
Phase 3	NCT02798471	Mar 2017 → May 2022	pulmonary embolism, venous thromboembolism	Daiichi Sankyo	Completed	No outcome recorded
Phase 3	NCT02672566	Jul 2016 → Sep 2019	fetal growth restriction	University Hospital of Saint-Etienne	Completed	No outcome recorded
Phase 3	NCT02486666	Mar 2016 → Dec 2022	venous thromboembolism	Hamilton Health Sciences Corporation	Unknown	No outcome recorded
Phase 3	NCT02271295	Jul 2015 → Jul 2019	cirrhosis of liver	Assistance Publique - Hôpitaux de Paris	Suspended	No outcome recorded
Phase 3	NCT01707732	Nov 2012 → Apr 2015	—	University Hospital, Rouen	Completed	No outcome recorded
Phase 3	NCT01356992	Jul 2012 → Jul 2013	intermediate coronary syndrome, myocardial infarction	Eurofarma Laboratorios S.A.	Terminated	No outcome recorded Stop: Business
Phase 3	NCT01573169	May 2012 → Mar 2020	hemorrhagic stroke, venous thromboembolism	University Of Perugia	Terminated	Missed primary Stop: Business
Phase 3	NCT01388322	Mar 2012 → Jun 2016	placental insufficiency, preeclampsia	Hospital Universitari Vall d'Hebron Research Institute	Completed	No outcome recorded
Phase 3	NCT01448746	Oct 2011 → Jan 2016	venous thromboembolism	The Catholic University of Korea	Unknown	Met primary
Phase 3	NCT01474902	Aug 2011 → Aug 2015	venous thromboembolism	The Hospital for Sick Children	Withdrawn	No outcome recorded Stop: Enrollment
Phase 3	NCT01058759	Nov 2009 → Feb 2011	non-small cell lung carcinoma	Hannover Medical School	Terminated	No outcome recorded Stop: Business
Phase 3	NCT01356329	Oct 2009 → Aug 2016	female reproductive system neoplasm	National Guard Health Affairs	Suspended	No outcome recorded Stop: Enrollment
Phase 3	NCT00986765	Jun 2009 → Nov 2015	preeclampsia	Assistance Publique - Hôpitaux de Paris	Completed	Missed primary
Phase 3	NCT00882635	Oct 2008 → Jun 2012	acute myocardial infarction	Robert Welsh	Completed	No outcome recorded
Phase 3	NCT00718471	Aug 2008 → Mar 2010	ST-elevation myocardial infarction	Assistance Publique - Hôpitaux de Paris	Completed	Missed primary
Phase 3	NCT00718354	Jul 2008 → Jan 2010	gastric cancer, gastroesophageal cancer	Thrombosis Research Institute	Completed	No outcome recorded
Phase 3	NCT00717938	Jun 2008 → May 2017	small cell lung carcinoma	Lund University Hospital	Completed	Missed primary
Phase 3	NCT00771563	Jun 2008 → Oct 2012	non-small cell lung carcinoma	University Hospital, Antwerp	Completed	No outcome recorded
Phase 3	NCT00673426	Jan → Mar 2008	kidney disorder	Azidus Brasil	Completed	No outcome recorded
Phase 3	NCT00740545	Apr 2007 → Sep 2013	—	University Hospital, Brest	Terminated	Missed primary
Phase 3	NCT00423319	Mar 2007 → Sep 2009	pulmonary embolism, venous thromboembolism	Bristol-Myers Squibb	Completed	Met primary
Phase 3	NCT00685958	Jul 2006 → Mar 2007	—	Sanofi	Completed	No outcome recorded
Phase 3	NCT00375076	Jun 2006 → May 2008	cancer	Medical University of Vienna	Completed	No outcome recorded
Phase 3	NCT00349180	Jun 2006 → ?	osteoarthritis, hip	Sanofi	Completed	No outcome recorded
Phase 3	NCT00328939	May 2004 → ?	venous thromboembolism	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00077792	Oct 2002 → Dec 2006	ST-elevation myocardial infarction	Sanofi	Completed	Met primary
Phase 3	NCT00043784	Aug 2001 → Feb 2005	intermediate coronary syndrome, myocardial infarction, myocardial ischemia	Sanofi	Completed	Mixed
Phase 3	NCT02181998	Jul 2000 → Aug 2002	myocardial infarction	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02181985	May 2000 → Apr 2001	myocardial infarction	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00182403	Sep 1998 → May 2004	pulmonary embolism, venous thromboembolism	McMaster University	Completed	No outcome recorded

Phase 449 trials · 3 met primary · 3 missed
Phase 4	NCT06845423	May 2025 → May 2028 expected	venous thromboembolism	University Hospital, Brest	Recruiting	No outcome recorded
Phase 4	NCT06442267	Jul 2024 → Jan 2027 expected	hemorrhagic disease, respiratory failure, thrombotic disease	Medical University of Vienna	Recruiting	No outcome recorded
Phase 4	NCT06133803	Jan → Dec 2024	female infertility	Fertility Center of Las Vegas	Unknown	No outcome recorded
Phase 4	NCT05735639	Jan 2024 → Jun 2027 expected	varicose disease, venous thromboembolism	Imperial College London	Recruiting	No outcome recorded
Phase 4	NCT07132515	Aug 2023 → Aug 2025 overdue	cirrhosis of liver, hepatocellular carcinoma, portal vein thrombosis	Mansoura University	Recruiting	No outcome recorded
Phase 4	NCT05672550	Jun 2023 → Aug 2025	—	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 4	NCT06114641	Jun 2023 → Feb 2024	—	PT Bio Farma	Completed	No outcome recorded
Phase 4	NCT05255003	Aug 2022 → Dec 2026 expected	blood coagulation disease, thrombocytopenia	Tzu-Fei Wang	Recruiting	No outcome recorded
Phase 4	NCT05245877	Aug 2022 → Aug 2026 overdue	hemorrhagic disease, malignant pancreatic neoplasm, thrombotic disease	Helsinki University Central Hospital	Recruiting	No outcome recorded
Phase 4	NCT04710732	Mar 2021 → Dec 2023	venous thromboembolism	Pirogov Russian National Research Medical University	Terminated	No outcome recorded
Phase 4	NCT04731558	Feb 2021 → Feb 2027 expected	hemorrhagic disease, liver cancer, pulmonary embolism, venous thromboembolism	Helsinki University Central Hospital	Recruiting	No outcome recorded
Phase 4	NCT04406389	Oct 2020 → Apr 2021	COVID-19	Weill Medical College of Cornell University	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT04861103	Oct 2020 → Dec 2026 expected	—	University of California, Irvine	Recruiting	No outcome recorded
Phase 4	NCT04409834	Aug 2020 → Mar 2022	COVID-19, thrombotic disease, venous thromboembolism	The TIMI Study Group	Completed	Mixed
Phase 4	NCT04584580	Aug → Oct 2020	COVID-19	Ain Shams University	Unknown	No outcome recorded
Phase 4	NCT04394377	Jun 2020 → Mar 2021	COVID-19	Brazilian Clinical Research Institute	Completed	Missed primary
Phase 4	NCT04360824	May 2020 → Apr 2021	COVID-19–associated multisystem inflammatory syndrome in adults	University of Iowa	Completed	No outcome recorded
Phase 4	NCT04520620	May → Jul 2020	COVID-19	University Hospital of Saint-Etienne	Withdrawn	No outcome recorded
Phase 4	NCT03664180	Jan 2019 → Nov 2022	ST-elevation myocardial infarction	Beijing Anzhen Hospital	Completed	Missed primary
Phase 4	NCT03701750	Nov 2018 → Oct 2021	infertility disorder	Shenzhen Zhongshan Urology Hospital	Unknown	No outcome recorded
Phase 4	NCT03568838	Jun 2018 → May 2020	myocardial infarction	Sheffield Teaching Hospitals NHS Foundation Trust	Completed	No outcome recorded
Phase 4	NCT04235569	Mar 2018 → Jan 2019	mitral valve disorder	Sarah Sabry Hashem	Completed	No outcome recorded
Phase 4	NCT03244020	Feb 2018 → Dec 2027 expected	bone sarcoma, hemorrhagic disease, soft tissue sarcoma, venous thromboembolism	Massachusetts General Hospital	Enrolling by invitation	No outcome recorded
Phase 4	NCT03146858	Aug → Dec 2017	strictly posterior acute myocardial infarction	Sheffield Teaching Hospitals NHS Foundation Trust	Completed	No outcome recorded
Phase 4	NCT03145675	May 2017 → Apr 2022	coronary artery disorder	Peking Union Medical College Hospital	Completed	Met primary
Phase 4	NCT02444572	Oct 2015 → Jul 2020	digestive system cancer, venous thromboembolism	Les Laboratoires des Médicaments Stériles	Completed	Met primary
Phase 4	NCT02658838	Apr 2015 → Aug 2016	—	Beijing Anzhen Hospital	Unknown	No outcome recorded
Phase 4	NCT03528967	Oct 2013 → Jul 2018	placental insufficiency	Les Laboratoires des Médicaments Stériles	Completed	No outcome recorded
Phase 4	NCT01916707	Jul 2013 → Jun 2017	venous thromboembolism	Intermountain Health Care, Inc.	Unknown	No outcome recorded
Phase 4	NCT01798550	Mar 2013 → Oct 2016	obesity disorder	Emory University	Completed	No outcome recorded
Phase 4	NCT01252420	Nov 2010 → Nov 2013	pulmonary embolism, venous thromboembolism	Monash Medical Centre	Unknown	No outcome recorded
Phase 4	NCT01608347	Jan 2010 → Sep 2012	pregnancy loss, recurrent, 4	Omar Mamdouh Shaaban	Completed	No outcome recorded
Phase 4	NCT00986076	Mar 2008 → Apr 2009	—	Iladevi Cataract and IOL Research Center	Completed	No outcome recorded
Phase 4	NCT00622648	Jan 2008 → Dec 2010	—	Sanofi	Completed	Missed primary
Phase 4	NCT00518245	Aug 2007 → Mar 2009	intermediate coronary syndrome	Canadian Heart Research Centre	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00585182	Jan 2007 → Apr 2008	obesity disorder, venous thromboembolism	University of Utah	Completed	No outcome recorded
Phase 4	NCT00412802	Dec 2006 → Mar 2009	acute coronary syndrome, kidney failure	French Cardiology Society	Completed	No outcome recorded
Phase 4	NCT00444652	Nov 2006 → Nov 2012	venous thromboembolism	University Hospital, Strasbourg, France	Unknown	No outcome recorded
Phase 4	NCT00347490	May 2006 → Apr 2007	—	Sanofi	Completed	No outcome recorded
Phase 4	NCT00253396	Oct 2005 → Jan 2007	—	Hamilton Health Sciences Corporation	Completed	No outcome recorded
Phase 4	NCT00265993	Dec 2004 → Jan 2009	venous thromboembolism	Sanofi	Completed	No outcome recorded
Phase 4	NCT00790387	Jun 2004 → Dec 2005	acute coronary syndrome	The Prince Charles Hospital	Completed	No outcome recorded
Phase 4	NCT00439855	Sep 2003 → Feb 2006	coronary artery disorder	Triemli Hospital	Completed	No outcome recorded
Phase 4	NCT00077805	Aug 2003 → Jul 2006	ischemic stroke	Sanofi	Completed	No outcome recorded
Phase 4	NCT00170378	Dec 2002 → Aug 2005	brain injury, venous thromboembolism	Hennepin Healthcare Research Institute	Completed	No outcome recorded
Phase 4	NCT00077818	Jun 2002 → Feb 2005	acute coronary syndrome	Sanofi	Completed	No outcome recorded
Phase 4	NCT00077753	Feb 2002 → Oct 2006	venous thromboembolism	Sanofi	Completed	Met primary
Phase 4	NCT00289042	Dec 1999 → Nov 2004	atrial fibrillation	The Cleveland Clinic	Completed	No outcome recorded
Phase 4	NCT00298285	? → Oct 2006	—	The Cleveland Clinic	Completed	No outcome recorded

Phase not applicable20 trials · 1 met primary · 1 missed
—	NCT07658989	May 2026 → Jan 2030 expected	cardiac valvular defect, pregnancy disorder	Mount Sinai Hospital, Canada	Recruiting	No outcome recorded
—	NCT07462182	Apr → Sep 2026 overdue	fetal growth restriction	Muhammad Aamir Latif	Not yet recruiting	No outcome recorded
—	NCT07506473	Apr 2026 → May 2028 expected	venous thromboembolism	University Hospital, Grenoble	Not yet recruiting	No outcome recorded
—	NCT06416566	May → Sep 2024	psoriasis	Zagazig University	Unknown	No outcome recorded
—	NCT04508439	Jun → Aug 2020	COVID-19, blood coagulation disease, pneumonia, pulmonary embolism	Hospital Regional de Alta especialidad de Ixtapaluca	Unknown	No outcome recorded
—	NCT04305756	Jun 2020 → Dec 2021	thrombotic disease, venous thromboembolism	University of Utah	Completed	Met primary
—	NCT04121611	Oct 2019 → Oct 2021	basilar artery occlusion	Sunnybrook Health Sciences Centre	Unknown	No outcome recorded
—	NCT04164693	Jan 2019 → Sep 2022	thrombotic disease	First Affiliated Hospital of Chongqing Medical University	Completed	No outcome recorded
—	NCT02600260	Dec 2014 → Jul 2019	pulmonary embolism, thrombophilia, venous thromboembolism	University of Sao Paulo General Hospital	Completed	No outcome recorded
—	NCT01763606	Dec 2012 → Apr 2019	—	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
—	NCT02085824	Jul 2012 → Apr 2014	osteoarthritis, hip	Centre of Postgraduate Medical Education	Unknown	No outcome recorded
—	NCT01356615	Mar 2011	end stage renal failure	Tehran University of Medical Sciences	Completed	No outcome recorded
—	NCT01696760	Oct 2010 → Dec 2012	bone neoplasm, musculoskeletal system cancer, soft tissue sarcoma, venous thromboembolism	Ohio State University Comprehensive Cancer Center	Completed	No outcome recorded
—	NCT00990236	Sep 2009 → Mar 2015	venous thromboembolism	Oregon Health and Science University	Completed	No outcome recorded
—	NCT01068795	Jul 2009 → Jan 2015	fetal growth restriction, placental abruption, preeclampsia, pregnancy disorder with abortive outcome +1	HaEmek Medical Center, Israel	Completed	Missed primary
—	NCT00836355	Apr → Dec 2009	ischemic stroke	NYU Langone Health	Terminated	No outcome recorded Stop: Enrollment
—	NCT01086046	Jan 2009 → Jun 2012	thrombotic disease	Third Military Medical University	Unknown	No outcome recorded
—	NCT00413374	May 2006 → Apr 2008	pulmonary embolism, venous thromboembolism	Brigham and Women's Hospital	Completed	No outcome recorded
—	NCT00420667	Nov 2004 → Mar 2005	coronary artery disorder	G. d'Annunzio University	Completed	No outcome recorded
—	NCT00321009	Mar 2000 → Apr 2004	acute myocardial infarction, coronary artery disorder	Corewell Health East	Completed	No outcome recorded

Comparator or background therapy204 trials
Phase 0	NCT03100123 Comparator	Nov 2017 → Oct 2019	antiphospholipid syndrome, pregnancy disorder with abortive outcome	Ottawa Hospital Research Institute	Terminated	No outcome recorded Stop: Enrollment
Phase 0	NCT00894283 Comparator	Jun 2009 → Sep 2013	pulmonary embolism, vein disorder	Johns Hopkins University	Completed	No outcome recorded
Phase 1	NCT07517289 Comparator	Apr → Jun 2026 overdue	—	Egyptian International Pharmaceutical Industries Co	Not yet recruiting	No outcome recorded
Phase 1	NCT06913595 Comparator	Mar 2024 → Oct 2025 overdue	venous thromboembolism	Cairo University	Active not recruiting	No outcome recorded
Phase 1	NCT03083704 Background	Feb → Sep 2017	hemorrhagic disease	Portola Pharmaceuticals	Completed	No outcome recorded
Show all 204 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 19

Date	Issuer	Release
2025-08-19	PT Bio Farma	Regulatory Bio Farma Raih Sertifikat Halal untuk Enoxaparin Sodium, Perkuat Akses Obat Halal di Indonesia co.id ↗ PT Bio Farma (Persero) resmi meraih Sertifikat Halal dari Badan Penyelenggara Jaminan Produk Halal (BPJPH) untuk produk Enoxaparin Sodium, menandai langkah penting dalam memperluas akses obat antikoagulan halal bagi masyarakat Indonesia.
2024-09-24	PT Bio Farma	Results Launching Hasil Post Marketing Surveillance Ovine Enoxaparin Sodium Bio Farma di ASMIHA 2024 co.id ↗ Hasil penelitian menunjukkan bahwa pada studi multisenter yang melibatkan 220 subjek di Pusat Jantung Nasional Harapan Kita (Jakarta), RSUP Dr. Sardjito (Yogyakarta), dan RSUP Prof. dr. I.G.N.G. Ngoerah (Bali) tersebut, ovine enoxaparin sodium dinilai setara (non-inferior) dari efikasi dan keamanan.
2023-06-07	Biological E. Limited	Regulatory BE’s Enoxaparin Sodium Injection Receives USFDA Approval biologicale.com ↗ Biological E. Limited (BE) is pleased to announce that it received final approval for an Abbreviated New Drug Application (ANDA) for the complex product Enoxaparin Sodium Injection USP, Pre-filled Syringes, from the U.S. Food and Drug Administration (USFDA) on June 06, 2023.
2020-03-29	Bayer	Results Rivaroxaban significantly reduced risk of major venous thromboembolism following nonmajor orthopaedic surgery bayer.com ↗ Bayer’s Factor Xa inhibitor, rivaroxaban (Xarelto™) reduced the risk of major venous thromboembolism (VTE) by about 75% in adult patients during a period of immobilization after nonmajor lower limb orthopaedic surgery, when compared to enoxaparin.
2019-03-19	Amphastar Pharmaceuticals, Inc.	Regulatory Amphastar Pharmaceuticals Receives FDA Approval for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) Multiple Dose Vial amphastar.com ↗ Amphastar Pharmaceuticals, Inc. , (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (FDA) granted approval of its Abbreviated New Drug Application (“ANDA”) for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) Multiple Dose Vial (MDV).
2017-03-13	Rovi Pharmaceuticals Laboratories	Regulatory Presentation on the biosimilar Enoxaparin of ROVI rovi.es ↗ DCP of ROVI's biosimilar of Enoxaparin completed with a positive outcome in Feb 2017.
2017-03-07	Rovi Pharmaceuticals Laboratories	Regulatory The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome. rovi.es ↗ It has been initiated, therefore, the national phase of the registration process, which is expected to be completed with the granting by the competent local authorities of the marketing authorisation in each concerned country.
2016-06-04	Halozyme Therapeutics	Results Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20 halozyme.com ↗ The safety profile continues to show the benefit of prophylactic enoxaparin use and the dataset continues to support our ongoing phase 3 study.
2015-12-10	Pfizer	Results AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism (VTE), VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy pfizer.com ↗ These findings indicate that the favorable benefit-to-risk profile of Eliquis was demonstrated early during treatment for VTE, including the use of a higher Eliquis dose of 10 mg twice daily for the initial seven days.
2015-05-31	Halozyme Therapeutics	Results Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients halozyme.com ↗ In the 20 PAG patients receiving 1 mg/kg/day of enoxaparin, no TE events have been reported to date.
2011-12-13	Daiichi Sankyo	Results Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery daiichisankyo.com ↗ Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery
2011-01-25	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Receives FDA Action Letter For Generic Lovenox® tevapharm.com ↗ The receipt of this action letter, called a Minor Deficiency letter, indicates that the FDA has completed its review of the ANDA including the Company's responses to key questions during the review process.
2010-12-22	Bristol-Myers Squibb	Results Newly Published Investigational Apixaban ADVANCE-3 Study Results Demonstrate Statistical Superiority to Enoxaparin with Comparable Rates of Bleeding in the Prevention of Venous Thromboembolism Following Total Hip Replacement Surgery bms.com ↗
2010-12-08	Daiichi Sankyo	Results EDOXABAN DEMONSTRATES SUPERIOR EFFICACY COMPARED WITH ENOXAPARIN SODIUM IN PREVENTING VTE AFTER TOTAL HIP REPLACEMENT daiichisankyo.com ↗ EDOXABAN DEMONSTRATES SUPERIOR EFFICACY COMPARED WITH ENOXAPARIN SODIUM IN PREVENTING VTE AFTER TOTAL HIP REPLACEMENT
2010-07-23	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Comments on Generic Lovenox® Approval tevapharm.com ↗ its subsequent approval of another generic filer's Abbreviated New Drug Application (ANDA).
2010-07-12	Daiichi Sankyo	Results EDOXABAN DEMONSTRATES SUPERIOR EFFICACY COMPARED WITH ENOXAPARIN SODIUM IN PREVENTING VTE AFTER TOTAL KNEE REPLACEMENT daiichisankyo.com ↗ Daiichi Sankyo Company, Limited announced that its investigational once-daily oral, direct factor Xa inhibitor, edoxaban, was shown to be superior toenoxaparin in preventing venous thromboembolic (VTE) events in patients following total knee replacement (TKR), a type of major orthopedic surgery.
2010-07-09	BioInvent International AB	Results Positive Results from Phase II VTE Prophylaxis Study with TB-402 (Anti-Factor VIII) Presented at the 21st Int. Congress on Thrombosis in Milan, Italy bioinvent.com ↗
2010-03-04	Bristol-Myers Squibb	Results ADVANCE-2 Study Results Demonstrate Investigational Anticoagulant Apixaban Was Statistically Superior to Enoxaparin in the Prevention of Venous Thromboembolism Following Knee Replacement Surgery bms.com ↗ The study results also showed numerically lower rates of major and clinically relevant non-major bleeding in patients treated with apixaban compared with those treated with enoxaparin.
2009-12-11	Daiichi Sankyo	Results Results of a Clinical Phase 3 Trial of an Oral Factor Xa Inhibitor, Edoxaban, in Prevention of Post-Operative Venous Thromboembolism daiichisankyo.com ↗ No significant difference between edoxaban and enoxaparin sodium groups was observed in the incidence of either major or clinically relevant non-major bleeding.

All press releases naming this drug 28 releases

Date	Issuer	Release
2025-08-19	PT Bio Farma	Bio Farma Raih Sertifikat Halal untuk Enoxaparin Sodium, Perkuat Akses Obat Halal di Indonesia co.id ↗
2024-09-24	PT Bio Farma	Launching Hasil Post Marketing Surveillance Ovine Enoxaparin Sodium Bio Farma di ASMIHA 2024 co.id ↗
2024-06-17	PT Bio Farma	Kembangkan Ovine Enoxaparin Sodium: Bio Farma gelar Exclusive Meeting bersama PERKI co.id ↗
2023-06-07	Biological E. Limited	BE’s Enoxaparin Sodium Injection Receives USFDA Approval biologicale.com ↗
2021-08-20	Zydus Lifesciences Limited	Zydus partners with CHEMI of Italy to launch Enoxaparin Sodium Injection in the United State zyduslife.com ↗
2021-02-02	Apotex Inc.	Apotex Corp. Issues Voluntary Nationwide Recall of Enoxaparin Sodium Injection, USP Due to Mislabeling of Syringe Barrel Measurement Markings apotex.com ↗
2020-03-29	Bayer	Rivaroxaban significantly reduced risk of major venous thromboembolism following nonmajor orthopaedic surgery bayer.com ↗
2019-03-19	Amphastar Pharmaceuticals, Inc.	Amphastar Pharmaceuticals Receives FDA Approval for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) Multiple Dose Vial amphastar.com ↗
2018-09-20	Rovi Pharmaceuticals Laboratories	ROVI announces an agreement with Biogaran for the marketing of its enoxaparin biosimilar in France rovi.es ↗
2018-09-19	Rovi Pharmaceuticals Laboratories	ROVI has commenced the marketing of its enoxaparin biosimilar in Spain rovi.es ↗
2018-06-12	Rovi Pharmaceuticals Laboratories	ROVI announces the agreement with Sandoz to distribute and market its Enoxaparin biosimilar rovi.es ↗
2018-04-24	Rovi Pharmaceuticals Laboratories	ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar rovi.es ↗
2017-03-13	Rovi Pharmaceuticals Laboratories	Presentation on the biosimilar Enoxaparin of ROVI rovi.es ↗
2017-03-13	Rovi Pharmaceuticals Laboratories	The biosimilar Enoxaparin, a great opportunity for ROVI rovi.es ↗
2017-03-07	Rovi Pharmaceuticals Laboratories	The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome. rovi.es ↗
2016-06-04	Halozyme Therapeutics	Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20 halozyme.com ↗
2015-12-10	Pfizer	AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism (VTE), VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy pfizer.com ↗
2015-05-31	Halozyme Therapeutics	Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients halozyme.com ↗
2015-02-17	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Bolsters Injectable Portfolio with Launch of Generic Lovenox® and Generic Zyvox® in the United States tevapharm.com ↗
2011-12-13	Daiichi Sankyo	Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery daiichisankyo.com ↗
2011-01-25	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Receives FDA Action Letter For Generic Lovenox® tevapharm.com ↗
2010-12-22	Bristol-Myers Squibb	Newly Published Investigational Apixaban ADVANCE-3 Study Results Demonstrate Statistical Superiority to Enoxaparin with Comparable Rates of Bleeding in the Prevention of Venous Thromboembolism Following Total Hip Replacement Surgery bms.com ↗
2010-12-08	Daiichi Sankyo	EDOXABAN DEMONSTRATES SUPERIOR EFFICACY COMPARED WITH ENOXAPARIN SODIUM IN PREVENTING VTE AFTER TOTAL HIP REPLACEMENT daiichisankyo.com ↗
2010-07-23	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Comments on Generic Lovenox® Approval tevapharm.com ↗
2010-07-12	Daiichi Sankyo	EDOXABAN DEMONSTRATES SUPERIOR EFFICACY COMPARED WITH ENOXAPARIN SODIUM IN PREVENTING VTE AFTER TOTAL KNEE REPLACEMENT daiichisankyo.com ↗
2010-07-09	BioInvent International AB	Positive Results from Phase II VTE Prophylaxis Study with TB-402 (Anti-Factor VIII) Presented at the 21st Int. Congress on Thrombosis in Milan, Italy bioinvent.com ↗
2010-03-04	Bristol-Myers Squibb	ADVANCE-2 Study Results Demonstrate Investigational Anticoagulant Apixaban Was Statistically Superior to Enoxaparin in the Prevention of Venous Thromboembolism Following Knee Replacement Surgery bms.com ↗
2009-12-11	Daiichi Sankyo	Results of a Clinical Phase 3 Trial of an Oral Factor Xa Inhibitor, Edoxaban, in Prevention of Post-Operative Venous Thromboembolism daiichisankyo.com ↗

Evidence & citations 27 cited values

Every value below carries the sentence it was read from. 384 sources stand behind the page.

Field	Value	Cited text
Known as	Enoxaparin Sodium	“SPECIFIC AIM: To test the safety and feasibility of using low molecular weight heparin (LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis) in lieu of unfractionated heparin...” NCT00289042 ↗ 40 “In this multicenter, randomized, open-label, active-comparator, phase 3 trial, 92 patients were randomized 2:1 to receive edoxaban 30mg once daily (n=62) or enoxaparin sodium...” PMID 24680549 ↗ Mar 2014 “Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or...” NCT01588171 ↗ “A Multinational, Multicentre, Randomized, Open, Parallel Group Study on the Efficacy and Safety of Bemiparin Sodium (LMWH) Compared to Enoxaparin Sodium (LMWH) in the Treatment...” NCT01880216 ↗ “Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment \[SRI\]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local...” NCT00679588 ↗ “For patients weighing less than 80kg, enoxaparin sodium 4000IU was administered once daily, while for those weighing over 80kg, enoxaparin sodium 4000IU was administered every 12 hours.” NCT04164693 ↗ “Multicenter, Non-comparative, Open-label Study to Evaluate the Safety and Efficacy of Enoxaparin Sodium (RP54563) 20 mg Bid for 14 Days in Patients With Hip Fracture Surgery” NCT00685958 ↗ “Enoxaparin Sodium (Clexane) is an anticoagulant used extensively and safely following bone (Orthopaedic) surgery to prevent blood clots from developing in the legs” NCT00232271 ↗ “The Enoxaparin sodium is one that acts as antithrombin-factor Xa inhibitor of acting directly on the inactivation of antithrombin.” NCT00673426 ↗ “Low Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day” NCT01590173 ↗ “Enoxaparin sodium 40 mg subcutaneous injection will be administered 12 hours before the operation” NCT06049758 ↗ Show 30 more sources
Known as	clexan	“HCC patient on anticogulant like Enoxaparin (clexan), warfarrin(marivan), or DOAC(apixaban)” NCT07132515 ↗
Known as	Clexane	“Following a first AV graft thrombosis and successful thrombolysis with angioplasty, patients on chronic hemodialysis will be randomized to s.c Enoxaparin (Clexane) 0.5 mg/1kg...” NCT01970280 ↗ 16 “The hypothesis of this trial is that the test drug (Enoxalow® - T) pharmacodynamics parameters are similar to the comparator drug (Clexane® - C) in healthy subjects following...” NCT01692171 ↗ “Enoxaparin Sodium (Clexane) is an anticoagulant used extensively and safely following bone (Orthopaedic) surgery to prevent blood clots from developing in the legs” NCT00232271 ↗ “LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.” NCT03044574 ↗ “Low molecular weigh heparins such as enoxaparin (clexane) have more favorable pharmacokinetic/ pharmacodynamic profiles, equivalent or improved efficacy” NCT00351663 ↗ “Enoxaparin (Clexane®) will be given at the recommended dose of 4,000 IU antiXa activity (40 mg/0.4 ml) once daily by SC injection for 14 days.” NCT04400799 ↗ “enoxaparin (100 mg/mL) 100-mg SC injection manufactured by Rovi Spain, or Clexane (100 mg/mL) 100-mg SC injection manufactured by Sanofi EU” NCT03363477 ↗ “Low Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day” NCT01590173 ↗ “Reference: Clexane (Enoxaparin Sodium 40mg/0.4ml) manufactured by Sanofi Aventis, Egypt.” NCT07517289 ↗ “Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily” NCT04274803 ↗ “Clexane (Heparin, Low-Molecular-Weight)- Sanofi-Aventis” NCT01692158 ↗ Show 6 more sources
Known as	ENOXAMED	“patients are given a curative dose of Enoxaparin (ENOXAMED)” NCT02152423 ↗
Known as	enoxaparin	“This prospective randomized trial will compare outcomes in patients receiving aspirin (81mg daily) in combination with a low-molecular weight heparin (LMWH) (enoxaparin...” NCT06133803 ↗ 339 “The initial dose will be a twice daily therapeutic dose of 1.35U/kg (pregnancy weight) of enoxaparin or 135 U/kg (pregnancy weight) of dalteparin using prefilled syringes...” NCT07658989 ↗ “PURPOSE: To determine if intraocular infusion of low-molecular-weight heparin (enoxaparin) reduces postoperative inflammation in pediatric eyes undergoing cataract surgery with...” PMID 22541652 ↗ Apr 2012 “Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI\<30 kg/m2 or 0.5 mg/kg Subcutaneously twice daily if...” NCT04360824 ↗ “For patients weighing less than 80kg, enoxaparin sodium 4000IU was administered once daily, while for those weighing over 80kg, enoxaparin sodium 4000IU was administered every 12 hours.” NCT04164693 ↗ “Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient.” NCT05848713 ↗ “Low molecular weight heparin Enoxaparin 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.” NCT04976465 ↗ “40 mg of enoxaparin injected subcutaneously every 24 hours starting the day of ovum pick-up to the documentation of fetal life by ultrasound at 7 weeks of gestation” NCT02861105 ↗ “Enoxaparin Sodium (Clexane) is an anticoagulant used extensively and safely following bone (Orthopaedic) surgery to prevent blood clots from developing in the legs” NCT00232271 ↗ “LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.” NCT03044574 ↗ “dose-adjusted warfarin (target INR 2-3) for 6 months + LMWH (enoxaparin 1 mg/kg q12h for a few days until INR target achieved) if indicated” NCT03490994 ↗ Show 329 more sources
Known as	Enoxaparin (Clexane)	“Enoxaparin (Clexane®)” NCT01817257 ↗
Known as	Enoxaparin (Lovenox)	“Enoxaparin (Lovenox)” NCT03465735 ↗
Known as	Enoxaparin sodium (preservative free)	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201476 ↗
Known as	Enoxaparin sodium salt	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201476 ↗
Known as	Enoxaparina de sodio	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201476 ↗
Known as	enoxaparine	“Clexane (enoxaparine) 40 mg sc” NCT00959621 ↗ 12 “Enoxaparine 4000 UI” NCT06845423 ↗ “Enoxaparine” NCT04536272 ↗ “Enoxaparine” NCT06913595 ↗ NCT00347490 ↗ NCT00328939 ↗ NCT02240927 ↗ NCT00740545 ↗ NCT01945879 ↗ NCT02411331 ↗ NCT02271295 ↗ Show 2 more sources
Known as	Enoxaparine sodique	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201476 ↗
Known as	Inhixa	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201476 ↗
Known as	Klexane	“Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 40 mg thromboprophylaxis every 24 hours for three days (72 hours)” NCT02474212 ↗ 1 “Klexane® (Enoxaparinsodium)” NCT00789308 ↗
Known as	Lovenox	“This prospective randomized trial will compare outcomes in patients receiving aspirin (81mg daily) in combination with a low-molecular weight heparin (LMWH) (enoxaparin...” NCT06133803 ↗ 17 “SPECIFIC AIM: To test the safety and feasibility of using low molecular weight heparin (LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis) in lieu of unfractionated heparin...” NCT00289042 ↗ “A Pilot Study to Determine the Feasibility of Conducting a Randomized Clinical Trial Comparing Fondaparinux Sodium (Arixtra) Once Daily With Enoxaparin (Lovenox®) Twice Daily...” NCT00894283 ↗ “All participants will receive one dose of pre-operative low molecular weight heparin (Lovenox®) subcutaneously, 2 hours prior to surgery.” NCT00769873 ↗ “Lovenox ® is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin.” NCT00633061 ↗ “Dexamethasone 20 mg PO Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg SQ Days 1-14” NCT00111748 ↗ “low dose or high dose enoxaparin (Lovenox), a blood thinner.” NCT03805672 ↗ “patients are given a curative dose of Enoxaparin (LOVENOX)” NCT02152423 ↗ “Lovenox® (enoxaparin), 4000 UI/day (+ Aspegic® (Aspirin))” NCT00986765 ↗ “enoxaparin (Lovenox) at the judgment of their physician.” NCT02070237 ↗ “Originator Enoxaparin with a trade name is Lovenox.” NCT06114641 ↗ Show 7 more sources
Known as	Lovenox (preservative free)	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201476 ↗
Known as	LovenoxTM	“Group A : Low Molecular Weight Heparin (LMWH), LovenoxTM (Enoxaparin)” NCT01356329 ↗
Known as	PK 10169	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201476 ↗
Known as	RP54563	“Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium（RP54563）20mg qd and 20mg Bid for 14 Days in Patients With Total Hip Replacement” NCT00349180 ↗ 2 “Multicenter, Non-comparative, Open-label Study to Evaluate the Safety and Efficacy of Enoxaparin Sodium (RP54563) 20 mg Bid for 14 Days in Patients With Hip Fracture Surgery” NCT00685958 ↗ “Evaluate the efficacy and safety of Enoxaparin Sodium (RP54563) 20mg Bid for 14 Days” NCT00723216 ↗
Known as	Thorinane	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201476 ↗
Known as	Versa	“Versa® (enoxaparin - Eurofarma)” NCT01356992 ↗
Known as	XRP4563	“Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)” NCT00349180 ↗ 2 “Enoxaparin sodium (XRP4563)” NCT00077792 ↗ “enoxaparin (XRP4563)” NCT00685958 ↗
Action	Activate	“Antithrombin-III activator” CHEMBL1201476 ↗
Action	Inhibit	“enoxaparin predominantly target factor Xa but to some extent also inhibit thrombin” PMID 19657123 ↗ Aug 2009
Modality	Other / unclassified	“low molecular weight heparin (LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis)” NCT00289042 ↗
Route	Subcutaneous	“Subcutaneous enoxaparin (n = 4993)” PMID 15238590 ↗ Jul 2004
Target	SERPINC1	“Antithrombin-III activator” CHEMBL1201476 ↗